Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance

Key Points Question Is prostate-specific antigen velocity associated with clinical progression in patients with low-risk prostate cancer treated with active surveillance, and are there differences between African American and non-Hispanic White patients? Findings In this population-based cohort study of 5296 patients with low-risk prostate cancer, prostate-specific antigen velocity was associated with clinical progression to more advanced disease. Compared with non-Hispanic White patients, African American patients were more likely to experience disease progression at lower prostate-specific antigen velocity thresholds. Meaning This study suggests that prostate-specific antigen velocity is a useful clinical tool for all patients treated with active surveillance, and African Americans may require closer attention to follow-up.